Buckingham Strategic Partners Immunity Bio, Inc. Transaction History
Buckingham Strategic Partners
- $8.25 Billion
- Q3 2025
A detailed history of Buckingham Strategic Partners transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Buckingham Strategic Partners holds 10,161 shares of IBRX stock, worth $21,134. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,161
Previous 13,001
21.84%
Holding current value
$21,134
Previous $34,000
29.41%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding IBRX
# of Institutions
297Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Vanguard Group Inc Valley Forge, PA27.7MShares$57.5 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...